ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Oncology · Breast Cancer Res Treat · 2026-08-13

Meta-analysis of 4 phase III trials (17,748 participants) of adjuvant CDK4/6 inhibitors in HR+/HER2− early breast cancer: iDFS benefit was similar in pre-/peri-menopausal (HR 0.80) and postmenopausal (HR 0.79) patients; no significant subgroup difference for iDFS or OS.

Meta-analysisn = 17,748
Bender et al. The impact of menopausal status on the efficacy of adjuvant CDK4/6 inhibitors in hormone receptor-positive early breast cancer: a systematic review and meta-analysis of phase III clinical trials
Oncology · Lancet Oncol · 2026-05-01

Meta-analysis of 11 phase 3 trials (6035 patients) with HR-positive, HER2-negative advanced breast cancer: CDK4/6 inhibitors plus endocrine therapy improved PFS and OS vs endocrine therapy alone; only abemaciclib and ribociclib showed significant OS benefit.

Meta-analysisn = 6,035
Beshr et al. CDK4/6 inhibitors plus endocrine therapy versus endocrine monotherapy in hormone receptor-positive, HER2-negative advanced breast cancer: a reconstructed individual patient data meta-analysis of phase 3 randomised controlled trials
Oncology · Cancer Treat Rev · 2025-12-16

Systematic review of 23 studies in HR+/HER2- breast cancer: CDK4/6 inhibitors plus endocrine therapy vs endocrine therapy alone raised grade 3/4 QTc prolongation risk (RR 1.83, driven by ribociclib) and VTE risk (RR 2.57, highest with abemaciclib).

Meta-analysisn = 23 studies
Hoo et al. Risk of QTc prolongation, and major cardiovascular adverse events associated with CDK4/6 inhibitors in hormone receptor-positive HER2-negative breast cancer - A systematic review and meta-analysis

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.